Targeting β1 integrin restores sensitivity to docetaxel of esophageal squamous cell carcinoma

Oncology Reports

Volumn 20, Issue 6, 2008, Pages 1345-1351

  Mori, Ryota ^a   Ishiguro, Hideyuki ^a   Kuwabara, Yoshiyuki ^a   Kimura, Masahiro ^a   Mitsui, Akira ^a   Tomoda, Keisuke ^a   Mori, Yoichiro ^a   Ogawa, Ryo ^a   Katada, Takeyasu ^a   Harata, Koshiro ^a   Fujii, Yoshitaka ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

1 integrin; Docetaxel; Esophageal squamous cell carcinoma; Small interfering RNA

Indexed keywords

BETA1 INTEGRIN; DOCETAXEL; MESSENGER RNA; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; TAXOID;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA MICROARRAY; DRUG SENSITIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE; BIOLOGICAL MODEL; CELL MOTION; DOSE RESPONSE; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; IC 50; METABOLISM; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANTIGENS, CD29; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, BIOLOGICAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TAXOIDS;

EID: 59249091316     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000150     Document Type: Article

References (28)

1. Beer TM, El Geneidi M and Eilers KM: Docetaxel (taxotere) in the treatment of prostate cancer. Expert Rev Anticancer Ther 3: 261-268, 2003.
2. Hong WK: The current status of docetaxel in solid tumors. An MD Anderson Cancer Center Review. Oncology 16: 9-15, 2002.
3. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25, 1992.
4. Blau HM and Baltimore D: Differentiation requires continuous regulation. J Cell Biol 112: 781-783, 1991.
5. Juliano RL: The role of beta 1 integrins in tumors. Semin Cancer Biol 4: 277-283, 1993.
6. Dedhar S and Hannigan GE: Integrin cytoplasmic interactions and bidirectional transmembrane signaling. Curr Opin Cell Biol 8: 657-669, 1996.
7. Hemler ME, Mannion BA and Berditchevski F: Association of TM4SF proteins with integrins: relevance to cancer. Biochim Biophys Acta 1287: 67-71, 1996.
8. Plath T, Detjen K, Welzel M, von Marschall Z, Murphy D, Schirner M, Wiedenmann B and Rosewicz S: A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor. J Cell Biol 150: 1467-1478, 2000.
9. Luo L, Salunga RC, Guo H, Bittner A, Joy KC, Galindo JE, Xiao H, Rogers KE, Wan JS, Jackson MR and Erlander MG: Gene expression profiles of laser-captured adjacent neuronal subtypes. Nat Med 5: 117-122, 1999.
10. Van Gelder RN, Von Zastrow ME, Yool A, Dement WC, Barchas JD and Eberwine JH: Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA 87: 1663-1667, 1990.
11. Kitahara O, Furukawa Y, Tanaka T, Kihara C, Ono K, Yanagawa R, Nita ME, Takagi T, Nakamura Y and Tsunoda T: Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res 61: 3544-3549, 2001.
12. Ono K, Tanaka T, Tsunoda T, Kitahara O, Kihara C, Okamoto A, Ochiai K, Takagi T and Nakamura Y: Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60: 5007-5011, 2000.
13. Fulton B and Spencer CM: Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 51: 1075-1092, 1996.
14. Avramis VI, Nandy P, Kwock R, Solorzano MM, Mukherjee SK, Danenberg P and Cohen LJ: Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells. Anticancer Res 18: 2327-2338, 1998.
15. Stein CA: Mechanisms of action of taxanes in prostate cancer. Semin Oncol 26: 3-7, 1999.
16. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U and Muller WJ: Targeted disruption of beta 1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6: 159-170, 2004.
17. Berry MG, Gui GP, Wells CA and Carpenter R: Integrin expression and survival in human breast cancer. Eur J Surg Oncol 30: 484-489, 2004.
18. Gui GP, Wells CA, Yeomans P, Jordan SE, Vinson GP and Carpenter R: Integrin expression in breast cancer cytology: a novel predictor of axillary metastasis. Eur J Surg Oncol 22: 254-258, 1996.
19. Shaw LM: Integrin function in breast carcinoma progression. J Mammary Gland Biol Neoplasia 4: 367-376,1999.
20. Zutter MM, Krigman HR and Santoro SA: Altered integrin expression in adenocarcinoma of the breast. Analysis by in situ hybridization. Am J Pathol 142: 1439-1448, 1993.
21. Aoudjit F and Vuori K: Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20: 4995-5004, 2001.
22. Damiano JS: Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets 2: 37-43, 2002.
23. Lewis JM, Truong TN and Schwartz MA: Integrins regulate the apoptotic response to DNA damage through modulation of p53. Proc Natl Acad Sci USA 99: 3627-3632, 2002.
24. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R and Haslett C: Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5: 662-668, 1999.
25. Kawamura T, Endo Y, Yonemura Y, Nojima N, Fujita H, Fujimura T, Obata T, Yamaguchi T and Sasaki T: Significance of integrin alpha2/beta1 in peritoneal dissemination of a human gastric cancer xenograft model. Int J Oncol 18: 809-815, 2001.
26. Fujita S, Watanabe M, Kubota T, Teramoto T and Kitajima M: Alteration of expression in integrin beta 1-subunit correlates with invasion and metastasis in colorectal cancer. Cancer Lett 91: 145-149, 1995.
27. Elliott BE, Ekblom P, Pross H, Niemann A and Rubin K: Antibeta 1 integrin IgG inhibits pulmonary macrometastasis and the size of micrometastases from a murine mammary carcinoma. Cell Commun Adhes 1: 319-332, 1994.
28. Bissell MJ, Weaver VM, Lelievre SA, Wang F, Petersen OW and Schmeichel KL: Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Res 59: 1757-1764, 1999.